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We read with interest Mark Fisher’s
review paper highlighting the very diffi-
cult decision-making many stroke physi-
cians and neurologists are facing around
the world on chronic anticoagulation for
atrial fibrillation (AF) (1). As the author
points out, oral anticoagulants are under-
utilized, often based on erroneous clin-
ical reasoning, which may over-estimate
bleeding risks. Part of the problem is that
current clinical scoring systems for bleed-
ing risk (e.g., HEMORR2HAGES, ATRIA,
and HAS-BLED) might be of limited value
in everyday clinical practice, especially in
regard to intracerebral hemorrhage (ICH),
the most feared and devastating compli-
cation of anticoagulation (2). The devel-
opment of advanced brain MR imaging
provides unique promise to tailor indi-
vidual treatment decisions on anticoagula-
tion by better balancing ICH and ischemic
stroke risks (2). New radiological markers
of cerebral small vessel disease (including
cerebral microbleeds, cortical superficial
siderosis, and white matter changes, etc.)
have the potential to provide information
about the presence of a hemorrhage-prone
microangiopathy, which seems to underlie
anticoagulation-related ICH (3–5).
We applaud the author’s new algo-
rithm incorporating cerebral microbleeds
on blood-sensitive MRI sequences (1);
however, before this approach can be
recommended in clinical practice some
potential limitations should be considered.
First, the data used to support the new algo-
rithm come from a heterogeneous group
of AF or stroke patients from very dif-
ferent study designs. In some of these
studies patients had suffered spontaneous
ICH (6, 7), in others previous ischemic
stroke (7–9), or no previous event (7).
Second, evidence largely comes from case–
control studies, which cannot prove causal-
ity. Third, data from patients with different
ethnic backgrounds might not be general-
izable to all populations (6, 8). For exam-
ple, the largest prospective study on CMBs
and stroke risk after ischemic stroke to
date included an Eastern (Asian) popu-
lation, and the vast majority (93.4%) of
patients with subsequent ICH had deep
CMBs likely reflecting the high prevalence
of hypertensive arteriopathy, with a low
prevalence of cerebral amyloid angiopathy
in this cohort. The distribution of CMBs
may be relevant for risk models. Further-
more, in a recent meta-analysis of CMBs
in ischemic stroke patients (9) the risk of
ICH increased up to eightfold in those with
CMB vs. those without, while the overall
stroke risk seemed to double. However, the
association between CMBs and subsequent
ICH was much stronger for Eastern (Asian)
compared to Western populations. These
data suggest that indeed in a subgroup
of patients, CMBs can potentially tip the
balance away from net clinical benefit for
anticoagulation, but this may not be gen-
eralizable across populations of different
ancestry. It must also be noted that in some
populations CMBs also confer a risk of
future ischemic stroke as well as ICH, with
no studies clearly addressing the balance of
future cerebral bleeding vs. ischaemia (10).
A new algorithm that incorporates MRI
to tailor individual treatment decisions
on anticoagulation in AF patients could
also take into account other hemorrhagic
and ischemic markers of cerebrovascu-
lar disease, such as cortical superficial
siderosis, small ischemic lesions (acute
or chronic), and white matter changes.
Finally, any algorithm that looks to tai-
lor individual treatment decisions in AF
should also incorporate alternative non-
pharmacological treatments. This is most
pertinent in those cases where anticoagu-
lation is contraindicated, or when the risks
of warfarin outweigh the benefits.
The vast majority of thrombus for-
mation in AF occurs in the left atrial
appendage. There is good evidence that
closure of this appendage can reduce risk
of ischaemic stroke (11–14), with demon-
stration of non-inferiority to warfarin (15).
All left atrial appendage devices how-
ever are still under evaluation, with cur-
rent evidence based on limited follow up
periods, small study numbers, and carry
risks of surgical complications. Moreover,
both the WATCHMAN and Amplatzer
devices require a short period of dual
antiplatelet therapy followed by life-long
monotherapy. It is for these reasons that
the European Society of Cardiology guide-
lines for the management of AF gave
these devices a grade 2B recommenda-
tion, which is: “consider in patients with
thromboembolic risk who cannot be man-
aged in the long-term using any form of
OAC” (16).
The innovative paper by Fisher et al.
is an important first step in personaliz-
ing anticoagulation treatment for AF. How-
ever, larger prospective studies using stan-
dardized MRI in a range of populations
treated with anticoagulants for AF patients
are urgently needed to provide reliable
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data to include in new treatment algo-
rithms (for example http://www.ucl.ac.uk/
cromis-2) (17). Such algorithms will then
need to be validated in other large popula-
tions before they can truly inform clinical
practice.
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